United Rheumatology Issues Clinical Practice Guidelines and Recommends the Vectra® DA Test for Adults with Rheumatoid Arthritis

SALT LAKE CITY, Utah, Dec. 22, 2016 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that United Rheumatology, a leading professional organization for rheumatologists in the United States with more that 300 members, has added Vectra® DA to its clinical practice guidelines for adults with rheumatoid arthritis (RA). The […]

Read More

Crescendo Bioscience Announces Four Studies with Vectra® DA Will Be Presented at the American College of Rheumatology 2016 Annual Meeting

Studies Advance the Knowledge of Vectra DA Utility for Clinicians and Patients with RA SALT LAKE CITY, Utah,  Nov. 12, 2016 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that four poster presentations on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held […]

Read More

Crescendo Bioscience Announces Four Poster Presentations at the American College of Rheumatology 2016 Annual Meeting

SALT LAKE CITY, Utah,  Oct. 3, 2016 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that four poster presentations on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov. 11-16, 2016 in Washington, D.C.  Vectra DA is the first and only multi-biomarker […]

Read More

Crescendo Bioscience Announces that New Data on Vectra® DA Will Be Presented at the European League Against Rheumatism 17th Annual Congress

Three Studies Demonstrate the Utility of Vectra DA to Help Predict Treatment Response and Remission in Patients with RA SALT LAKE CITY, Utah, June 10, 2016 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that new data on the use of Vectra® DA test to predict treatment response in […]

Read More